Advanced Gastroesophageal Cancer

Publication Date: January 5, 2023

Key Points

Key Points

  • Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
  • Most gastric and gastrointestinal junction tumors are adenocarcinoma.
  • Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.

Treatment

...Treatment...

...1. Immunotherapy and Targeted Thera...


...First...

...1.1For HER2-negative patients with gast...

...tion 1.2For HER2-negative patients w...

...endation 1.3For patients with ESCC a...

...mendation 1.4For patients with ESCC, and PD-L...

...endation 1.5For patients with HER2-p...


...Second- or Thir...

...tion 2.1For patients with advanced gastroesopha...

...tion 2.2For HER2-positive patients with...